Glaxo Releases Halted Phase III Tykerb Data; Drug Could Be Strong Rx for Breast Cancer | GenomeWeb

ATLANTA — GlaxoSmithKline last week released data from a phase III trial of its Tykerb breast cancer drug that it halted in April, and the results suggest that the drug is poised to become the next targeted therapy for that indication.

However, roles for Tykerb in other potential indications, such as renal cancer, seem less clear, according to phase II and III data presented here last week at the American Society of Clinical Oncology's 2006 meeting, held here this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.